AGT2 + AGZ

AGT2 + AGZ is an investigational fixed-dose combination of two small molecule drugs, AGT2 and AGZ, developed for the treatment of primary hypercholesterolemia. The combination is being evaluated in a multi-center, randomized, double-blind, active-controlled phase 3 clinical trial to assess its efficacy and safety compared to monotherapy with either component. Both agents are administered orally as tablets once daily. The precise mechanisms of action and molecular targets for both components have not been publicly disclosed; however, the therapeutic area is endocrinology and metabolic disease with a focus on lowering LDL cholesterol levels in patients with primary hypercholesterolemia[1][2][3][4].